title: RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?
authors.affiliation: University of Michigan Medical Center, Pediatric Critical Care Service, ann Arbor 48109-0243, USA. fmoler@umich.edu
authors.forename: F W
authors.initials: FW
authors.lastname: Moler
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006760:Hospitalization / Q000191:economics; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics* / Q000627:therapeutic use; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016756:Immunoglobulins, Intravenous; C098685:respiratory syncytial virus immune globulin intravenous; D000069455:Palivizumab